尿激酶静脉溶栓治疗急性缺血性卒中/短暂性脑缺血发作的院内死亡率及相关影响因素的多中心分析

doi:10.3969/j.issn.1673-5765.2020.10.009

摘要/Abstract

摘要：

目的探讨尿激酶静脉溶栓治疗急性缺血性卒中/TIA患者的院内死亡率及其影响因素。方法回顾性分析2013年1月-2016年5月河南省11家市级、县级医院神经内科连续收治的发病6 h内接受尿激酶静脉溶栓治疗的急性缺血性卒中和TIA患者的临床资料，统计院内全因死亡率，采用多因素Logistic回归分析院内死亡的相关影响因素。结果共入组444例患者，平均年龄60.19±11.61岁，男性296例（66.7%），院内死亡25例（5.6%）。多因素Logistic回归分析显示，发病至溶栓时间3～6 h（OR 3.006，95%CI 1.120～8.071，P =0.029）、溶栓前 NI HSS评分（OR 1.130，95%CI 1.079～1.183，P＜0.001）及心房颤动病史（OR 3.671，95%CI 1.282～10.511， P =0.015）是尿激酶静脉溶栓治疗急性缺血性卒中/TIA患者院内死亡的独立影响因素。结论发病至溶栓时间3～6 h、严重神经功能损害、心房颤动病史是尿激酶静脉溶栓治疗急性缺血性卒中/TIA患者住院期间死亡的独立危险因素。

文章导读： 急性缺血性卒中患者尿激酶静脉溶栓治疗住院期间死亡率与发病至溶栓时间、神经功能损害程度、心房颤动病史有关。

关键词: 尿激酶; 缺血性卒中; 死亡率; 危险因素

Abstract:

Objective To investigate the inhospital mortality and related risk factors in patients with acute ischemic stroke (AIS) or TIA who received urokinase intravenous thrombolysis. Methods The data of AIS and TIA patients who received urokinase intravenous thrombolysis treatment within 6 hours after onset from 11 hospitals in Henan province were retrospectively analyzed. Baseline data and inhospital mortality were collected. Multivariate logistic regression analysis was used to identify the independent risk factors for inhospital death. Results A total of 444 patients were included, with a mean age of 60.19±11.61 years old and 296 males (66.7%). There were 25 (5.6%) inhospital deaths. Multivariate analysis showed that thrombolysis in the 3-6 hour time window (OR 3.006, 95%CI 1.120-8.071, P =0.029), NIHSS score at admission (OR 1.130, 95%CI 1.079-1.183, P <0.001), atrial fibrillation (OR 3.671, 95%CI 1.282- 10.511, P =0.015), were independent risk factors for inhospital death after urokinase thrombolysis. Conclusions Intravenous thrombolysis in the 3-6 hour time window, NIHSS score at admission, atrial fibrillation were independent risk factor for inhospital death after urokinase intravenous thrombolysis in AIS/TIA patients.

Key words: Urokinase; Ischemic stroke; Mortality; Risk factor

刘凯，王伊龙，李子孝，张心邈，高远，何明峰，郭学芳，赵艳艳，韩新生，赵明枝，岳建华，张平，赵建华，闫红光，毛向莹，刘金峰. 尿激酶静脉溶栓治疗急性缺血性卒中/短暂性脑缺血发作的院内死亡率及相关影响因素的多中心分析[J]. 中国卒中杂志, 2020, 15(10): 1078-1082.

LIU Kai, WANG Yi-Long, LI Zi-Xiao, ZHANG Xin-Miao, GAO Yuan, HE Ming-Feng,GUO Xue-Fang, ZHAO Yan-Yan, HAN Xin-Sheng, ZHAO Ming-Zhi, YUE Jian-Hua, ZHANG Ping, ZHAO Jian-Hua,YAN Hong-Guang, MAO Xiang-Yi. Inhospital Mortality and Related Influencing Factors in Acute Ischemic Stroke Patients Treated with Urokinase Intravenous Thrombolysis[J]. Chinese Journal of Stroke, 2020, 15(10): 1078-1082.

参考文献

[1] GBD 2013 Mortality and Causes of Death

Collaborators. Global，regional，and national agesex

specific all-cause and cause-specific mortality

for 240 causes of death，1990-2013：a systematic

analysis for the Global Burden of Disease Study

2013[J]. Lancet，2015，385（9963）：117-171.

[2] LIU M，WU B，WANG W Z，et al. Stroke in

China：epidemiology，prevention，and management

strategies[J]. Lancet Neurol，2007，6（5）：456-464.

[3] 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组. 中国急性缺血性脑卒中诊治指南

2018[J]. 中华神经科杂志，2018，51（9）：666-682.

[4] POWERS W J，RABINSTEIN A A，ACKERSON

T，et al. 2018 Guidelines for the early management of

patients with acute ischemic stroke：a guideline for

healthcare professionals from the American Heart

Association/American Stroke Association[J/OL].

Stroke，2018，49（3）：e46-e110[2019-01-01].

https：//doi.org/10.1161/STR.0000000000000158.

[5] DEMAERSCHALK B M，KLEINDORFER D

O，ADEOYE O M，et al. Scientific rationale for

the inclusion and exclusion criteria for intravenous

alteplase in acute ischemic stroke：a statement for

healthcare professionals from the American Heart

Association/American Stroke Association[J]. Stroke，

2016，47（2）：581-641.

[6] National Institute of Neurological Disorders

and Stroke rt-PA Stroke Study Group. Tissue

plasminogen activator for acute ischemic stroke[J].

N Engl J Med，1995，333（24）：1581-1587.

[7] HACKE W，KASTE M，BLUHMKI E，et al.

Thrombolysis with alteplase 3 to 4.5 hours after

acute ischemic stroke[J]. N Eng J Med，2008，359

（13）：1317-1329.

[8] LEES K R，BLUHMKI E，VON KUMMER R，et

al. Time to treatment with intravenous alteplase

and outcome in stroke：an updated pooled analysis

of ECASS，ATLANTIS，NINDS，and EPITHET

trials[J]. Lancet，2010，375（9727）：1695-1703.

[9] 国家“九五”攻关课题协作组. 急性脑梗死六小时

以内的静脉溶栓治疗[J]. 中华神经科杂志，2002，35

（4）：210-213.

[10] 陈清棠，贺茂林，徐忠宝，等. 急性脑梗死（6 h以内）

静脉溶栓治疗[J]. 中风与神经疾病杂志，2001，18

（5）：259-261.

[11] 中华医学会神经病学分会脑血管病学组急性缺血

性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中

诊治指南2014[J]. 中华神经科杂志，2015，48（4）：

246-257.

[12] YU A Y，HILL M D，COUTTS S B. Should minor stroke patients be thrombolyzed? A focused review

and future directions[J]. Int J Stroke，2015，10（3）：

292-297.

[13] COUTTS S B，DUBUC V，MANDZIA J，et al.

Tenecteplase-tissue-type plasminogen activator

evaluation for minor ischemic stroke with proven

occlusion[J]. Stroke，2015，46（3）：769-774.

[14] WANG Y L，WU D，LIAO X L，et al. Burden of

stroke in China[J]. Int J Stroke，2007，2（3）：211-

213.

[15] LAURENCIN C，PHILIPPEAU F，BLANCLASSERRE

K，et al. Thrombolysis for acute

minor stroke：outcome and barriers to management.

Results from the RESUVAL stroke network[J].

Cerebrovasc Dis，2015，40（1/2）：3-9.

[16] 王伊龙，赵性泉，刘新峰，等. 高危非致残性缺血

性脑血管事件诊疗指南[J]. 中国卒中杂志，2016，11

（6）：481-491.

[17] SAVER J L，FONAROW G C，SMITH E E，et

al. Time to treatment with intravenous tissue

plasminogen activator and outcome from acute

ischemic stroke[J]. JAMA，2013，309（23）：2480-

2488.

[18] MITEFF F，LEVI C R，BATEMAN G A，et al.

The independent predictive utility of computed

tomography angiographic collateral status in acute

ischaemic stroke[J/OL]. Brain，2009，132（Pt 8）：

2231-2238[2019-01-01]. https：//doi.org/10.1093/

brain/awp155.

[19] TU H T，CAMPBELL B C，CHRISTENSEN S，et

al. Pathophysiological determinants of worse stroke

outcome in atrial fibrillation[J]. Cerebrovasc Dis，

2010，30（4）：389-395.

[20] SAPOSNIK G，GLADSTONE D，RAPTIS R，et

al. Atrial fibrillation in ischemic stroke：predicting

response to thrombolysis and clinical outcomes[J].

Stroke，2013，44（1）：99-104.

[21] SEET R C，ZHANG Y，WIJDICKS E F，et al.

Relationship between chronic atrial fibrillation and

worse outcomes in stroke patients after intravenous

thrombolysis[J]. Arch Neurol，2011，68（11）：1454-

1458.

[22] 梅晶，李惠允，杨珩，等. 急性缺血性卒中患者静脉

溶栓效果的影响因素分析[J]. 中国临床保健杂志，

2016，19（1）：12-15.

[23] 龙汉春，彭国光，陈映，等. 心房颤动对不同治疗时

机下脑梗死患者静脉溶栓效果影响的研究[J]. 中国

现代医学杂志，2016，26（4）：104-107.

[24] 李晓波，黄敏，陈蓓蕾，等. 急性脑梗死合并心房颤

动患者的重组组织型纤溶酶原激活剂静脉溶栓治疗

[J]. 中华老年医学杂志，2016，35（1）：22-26.

[25] 郭岩，张翠宏，王海洋，等. 伴心房颤动的急性脑梗

死不同时间窗行重组组织型纤溶酶原激活剂静脉

溶栓治疗的疗效观察[J]. 中华医学杂志，2016，96

（26）：2054-2058.